European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Robust Automation and Point of Care IDentification of COVID

Descripción del proyecto

Una estrategia global para el diagnóstico preciso de la COVID-19 y otras afecciones respiratorias

La COVID-19, la enfermedad infecciosa causada por el coronavirus descubierto más recientemente, se ha extendido a más de doscientos países en todo el mundo. Es importante saber detectar y diferenciar el coronavirus SARS-CoV-2 del SARS-CoV, que apareció en noviembre de 2002, así como de otros treinta virus y bacterias respiratorios comunes. La incapacidad para distinguir los distintos patógenos podría dar lugar a un uso innecesario de agentes antimicrobianos, la infección cruzada de pacientes incorrectamente agrupados y una mayor propagación de enfermedades infecciosas. El proyecto financiado con fondos europeos RAPID-COVID establecerá el prototipo de una técnica para detectar y distinguir de manera simultánea el SARS-CoV-2 y otros treinta virus y bacterias respiratorios comunes. Permitirá un diagnóstico amplio, preciso y rentable durante el brote actual, así como una mejor integración en los futuros diagnósticos rutinarios de las enfermedades respiratorias.

Objetivo

As of 30th March 2020, the COVID-19 outbreak had caused over 735,000 infections globally, claiming more than 35,000 lives. By the end of July 2020 these numbers have increased globally to more than 17 millions infections and more than 660,000 lives have been lost due to the disease. Rapid and definitive diagnosis of the specific SARS-CoV-2 is essential, while identifying other common viral and bacterial pathogens is beneficial in the management of treatment and in timely isolation of infected patients with overlapping clinical symptoms.

A recent study has shown that 5.8% of SARS-CoV-2 infected and 18.4% of non-SARS-CoV-2-infected patients had other concurrent pathogen infections. Failure to distinguish different pathogens may lead to unnecessary antimicrobial use, cross-infection of mis-grouped patients and further spreading of the infection. Therefore, in response to the current outbreak, singleplex testing is not optimal, especially considering the virus may become permanently and globally endemic.

Simple, sensitive and multiplex detection of all respiratory pathogens is technically challenging. In response to the need for faster and better detection of multiple respiratory pathogens, GeneFirst has developed a prototype using its innovative proprietary technology - MPA (Multiplex Probe Amplification) - to simultaneously detect and differentiate SARS-CoV-2 as well as 30 other common respiratory bacteria and viruses.

This assay will allow for accurate, cost-effective and comprehensive diagnoses during the current outbreak as well as future routine diagnosis. In this project, the consortium aims to analytically and clinically validate (CE-mark) this assay on two automated platforms for Point-of-Care and core pathology testing. This strategy provides maximum flexibility in screening and triage, allowing better and faster care, alleviating pressures on healthcare systems and improving patient recovery rates. GeneFirst aim to commercialise the assay for £8.50 (€9.00) per test.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

GENEFIRST LIMITED
Aportación neta de la UEn
€ 1 005 687,50
Dirección
BUILDING E5 CULHAM SCIENCE CENTRE
OX14 3DB Abingdon
Reino Unido

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 005 687,50

Participantes (4)